Objective To systematically evaluate the efficacy of treatments for tics and the risks associated with their use.
This article summarizes the findings of a systematic review, conducted as the foundation of an American Academy of Neurology (AAN) practice guideline on the treatment of tics in people with Tourette syndrome (TS) and chronic tic disorders. A companion article summarizes the assessment and treatment recommendations and suggestions for future research. The complete and unabridged practice guideline (systematic review, recommendations, and suggestions for future research) is available at links.lww.com/WNL/A883 and includes full details of the methodology used, including the risk of bias assessment for each study, meta-analysis, and confidence in evidence determinations; space restrictions precluded more detailed description in this article.
TS is a neurodevelopmental condition that is characterized by the presence of multiple motor tics and at least 1 vocal tic that persists for at least 1 year. 1 Motor tics are defined as sudden, rapid, recurrent, and nonrhythmic movements. Vocal tics are essentially motor tics that involve the nasal or respiratory muscles, resulting in simple sounds such as sniffing, throat clearing or coughing, or complex vocalizations, including coprolalia, but they also may manifest with speech blocking or stuttering-like symptoms. Tics are often accompanied by specific behavioral symptoms. 2, 3 Persistent (chronic) motor tic disorder is characterized by the presence of motor tics only, which persist for more than 1 year. Persistent (chronic) vocal tic disorder is characterized by the presence of vocal tics only, which persist for more than 1 year. Epidemiologic studies that used current diagnostic criteria have consistently shown that the prevalence figures for TS in school children range from 0.4% to 1.5% across all cultures, while the prevalence of chronic tic disorders ranges from 0.9% to 2.8%. 4 There are few population-based estimates of the prevalence of TS in adults; one recent population-based study found a prevalence of diagnosed TS of approximately 1 per 1,000. 5 TS and chronic tic disorders are believed to share a common neurobiological origin, and we use the abbreviation TS throughout the article to refer to all individuals with primary chronic tic disorders.
The majority of patients with TS, both in specialist clinics and in the community, report the presence of behavioral symptoms associated with their tics: most commonly obsessivecompulsive disorder (or obsessive-compulsive behavior) and attention-deficit/hyperactivity disorder (ADHD). 6 Lifetime prevalence of comorbid behavioral disorders is estimated to approach 90%. 7 Patients with TS also report higher rates of impulse control, anxiety, and affective disorders compared with people in the general population. 7, 8 It is worth noting that the associated behavioral comorbidities often compromise the overall well-being of patients with TS to a much greater extent than tic severity. 9, 10 The purpose of this systematic review is to assess all randomized controlled trials that evaluate the efficacy of medical and behavioral treatments for tics, including neurostimulation, and the risks associated with their use. The systematic review was performed to develop recommendations pertaining to the treatments of tics in children and adults with TS or chronic tic disorders. Antipsychotic medications have been commonly prescribed for this purpose since the 1960s. The adverse effects associated with antipsychotic medications, including movement disorders such as acute and tardive dystonia, tardive dyskinesia, akathisia, and drug-induced parkinsonism, and metabolic adverse effects, such as weight gain, hyperlipidemia, and hyperglycemia, have led clinicians to search for other effective treatments. In recent years, there has been a resurgence in the interest in behavioral treatments and neuromodulation for tics, yielding expanding evidence in this area.
Clinical questions
The systematic review for this practice guideline addressed the following questions:
1. In children and adults with TS or a chronic tic disorder, which medical, behavioral, and neurostimulation interventions, compared with placebo or other active interventions, improve tic severity? 2. In children and adults with TS or a chronic tic disorder, what are the risks of harm, including weight gain, elevated prolactin levels, sedation, drug-induced movement disorders, hypotension, bradycardia, and ECG changes with medical treatments, compared with placebo or other active interventions?
Description of the analytic process In May 2016, the Guideline Development, Dissemination, and Implementation (GDDI) Subcommittee of the AAN recruited a multidisciplinary panel to develop the guideline, including 9 physicians, 2 psychologists, and 2 patient representatives. The patient representatives are both associated with the Tourette Association of America. All panel members
Supplemental Data Full measurement set NPub.org/vsmv3e were required to submit online conflict of interest (COI) forms and copies of their curriculum vitae. All authors determined to have COI were not permitted to review or rate the evidence.
This evidence-based practice guideline follows the methodologies described in the 2011 edition of the AAN's guideline development process manual, 11 as amended to include use of the revised scheme for classifying therapeutic articles, the GDDI Guideline Topic Nomination Process scoring tool, and the change in order of steps for external review.
Study screening and selection criteria: Inclusion criteria for article selection We included systematic reviews and randomized controlled trials on the treatment of tics in individuals with TS or chronic tic disorders that included at least 20 participants (10 participants if a crossover trial), except for neurostimulation trials, for which no minimum sample size was required. To obtain additional information on drug safety, we included cohort studies or case series that specifically evaluated adverse drug effects in individuals with TS.
Types of participants
We included individuals with TS or chronic tic disorders of any age or sex.
Types of intervention
We included any medical, behavioral, or neurostimulation (e.g., transcranial magnetic stimulation, deep brain stimulation [DBS]) intervention for tics.
Comparison group
We included studies that compared medical, behavioral, or neurostimulation treatments with placebo or other active treatments.
Types of outcome measures
We assessed the effect of all treatments on measures of tic severity and tic-related impairment. The preferred instrument for evaluation of tic severity and tic-related impairment was the Yale Global Tic Severity Scale (YGTSS), and when outcome results with this instrument were reported, they were used to calculate effect size. The YGTSS, the most extensively deployed rating scale for tics internationally, has displayed very good internal consistency, interrater reliability, and convergent and divergent validity. 12 Weight gain was assessed through reported measurements in kilograms. Elevated prolactin levels were evaluated by assessing mean changes in prolactin levels between groups, or mean prolactin levels at endpoint between groups. Drug-induced movement disorders were based on assessments that used validated scales, including the Extrapyramidal Symptoms Rating Scale, Barnes Akathisia Scale, Simpson Angus Scale, or the Abnormal Involuntary Movement Scale, or by clinician report. Sedation was evaluated by patient/parent/clinician report and assessment. Hypotension and bradycardia were evaluated by assessing reported changes in systolic and diastolic blood pressure and heart rate with treatment and reported rates of presyncope and syncope. Reported ECG changes were also included.
The initial search was conducted in August 2016 and included MEDLINE, EMBASE, PsychINFO, CENTRAL, and ClinicalTrials.gov. The total number of references retrieved after duplicates were removed was 2,196. After 2 reviewers, working independently of each other, reviewed the abstracts and titles of these 2,196 references, the articles for 192 were selected and obtained for full-text review. This included 16 systematic reviews, for which the references of all included studies were examined for missing studies. Four additional studies were identified using this method. In total, 66 randomized controlled trials and 12 studies that evaluated drug safety were included in our analysis. Two nonconflicted panel members rated the class of evidence for each article according to the AAN scheme for classification of therapeutic articles (revised as denoted in a 2011 process manual amendment). Disagreements were resolved by a third panel member. Outcome data from included studies were extracted by the guideline methodologist and verified by a second panel member.
A repeat search was conducted in September 2017 to update our search results, with a total of 211 new abstracts retrieved after duplicate removal. Seven abstracts were selected for fulltext review, and 3 articles met our inclusion criteria and were added to the analysis.
The effect size, or standardized mean difference (SMD), was calculated for each study intervention/outcome pair. The SMD expresses the size of the intervention effect relative to the variability observed in each study. For our analysis, an SMD of 0.20 was considered the minimal clinically meaningful difference for reduction in tic severity; effect sizes smaller than 0.10 were considered clinically unimportant. There were a number of studies that did not provide adequate data to reliably calculate effect sizes. [13] [14] [15] [16] [17] [18] [19] [20] If multiple studies were available that evaluated the same intervention/ outcome pair, only those studies with the lowest risk of bias were used in formulating the confidence in evidence statements. A random effects meta-analysis was performed when appropriate to synthesize results of trials that studied the same intervention and outcome.
A modified form of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to develop conclusions. 21 The confidence in the evidence (high, moderate, low, or very low) is anchored to the error domain-class of evidence, indirectness of evidence, and precision of effect estimate-with the highest risk of error (see unabridged practice guideline for complete details on the evidence synthesis process).
Analysis of evidence
In children and adults with TS or a chronic tic disorder, which medical, behavioral, and neurostimulation interventions, compared with placebo or other active interventions, improve tic severity? Unless otherwise specified, trial participants included both children (individuals aged 18 years and younger) and adults (individuals older than 18 years).
High confidence in the evidence
People with tics receiving the Comprehensive Behavioral Intervention for Tics are more likely than those receiving supportive psychotherapy to have reduced tic severity (SMD 0.56; 95% confidence interval [CI] 0.31-0.82, high confidence, 2 Class I studies 22, 23 ).
Moderate confidence in the evidence
People with tics receiving the following interventions are probably more likely than those receiving placebo to have reduced tic severity: 36 ; confidence in evidence upgraded due to magnitude of effect (children only). Desipramine is now rarely used in children after several case reports of sudden death associated with the use of this medication. 37 People with tics receiving active DBS of the globus pallidus are probably more likely than those receiving sham DBS of the globus pallidus to have reduced tic severity (SMD 0.77 [95% CI 0.14- For people with tics and a comorbid diagnosis of ADHD, atomoxetine does not worsen tics relative to placebo (1 Class II study 49 ) (children only).
Very low confidence in the evidence
There is insufficient evidence to determine whether people with tics receiving the following interventions are more or less likely than those receiving placebo to have reduced tic severity: 13 In children and adults with TS or a chronic tic disorder, what are the risks of harm, including weight gain, elevated prolactin levels, sedation, drug-induced movement disorders, hypotension, bradycardia, and ECG changes with medical treatments compared with placebo or other active interventions? Data on harms related to the use of DBS can be found in the complete and unabridged practice guideline.
Weight gain
People with tics receiving risperidone are probably more likely to gain weight than people receiving placebo (moderate confidence, 2 Class II studies 27,e1 ).
People with tics receiving aripiprazole are probably more likely to gain weight than those receiving placebo (moderate confidence, 1 Class I study 28 and I Class II study 29 ) (children only).
People with tics receiving aripiprazole are possibly more likely to have an increase in body mass index and waist circumference than people receiving placebo (low confidence, I Class II study 29 ) (children only).
People with tics and a comorbid diagnosis of ADHD who are receiving atomoxetine are possibly more likely to have a decrease in body weight than people receiving placebo (low confidence, 1 Class II study 49 ) (children only).
Elevated prolactin levels
People with tics receiving pimozide are possibly more likely to have increased prolactin levels than people receiving placebo (low confidence, 1 Class II study 24 ).
People with tics receiving haloperidol are possibly more likely to have increased prolactin levels than people receiving placebo (low confidence, 1 Class II study 24 ).
People with tics receiving metoclopramide are possibly more likely to have greater increases in prolactin levels than people receiving placebo (low confidence, 1 Class II study 42 ) (children only).
Sedation
People with tics receiving risperidone are possibly more likely to experience fatigue and somnolence than people receiving placebo (low confidence, 1 Class II study 26 ).
People with tics receiving aripiprazole are possibly more likely to experience sedation and somnolence than people receiving placebo (low confidence, 1 Class II study 29 ) (children only).
People with tics receiving tiapride are probably more likely to experience higher rates of physical tiredness and sleep disturbances compared with people receiving placebo (moderate confidence, 1 Class I study 30 ) (children only).
People with tics receiving clonidine are probably more likely to experience sedation than people receiving placebo (moderate confidence, 1 Class I study 31 and 1 Class II study 33 ).
People with tics receiving guanfacine are probably more likely than those receiving placebo to have drowsiness (moderate confidence, 1 Class I study 43 ) (children only).
Drug-induced movement disorders
People with tics receiving pimozide are probably more likely to have extrapyramidal symptoms than people receiving placebo (moderate confidence, 2 Class II studies 40 ).
People with tics receiving haloperidol are possibly more likely to have extrapyramidal symptoms than people receiving pimozide and placebo (low confidence, 1 Class II study 24, 25 ).
People with tics receiving risperidone are possibly more likely to have higher parkinsonism scores on the Extrapyramidal Symptom Rating Scale Score than people receiving placebo (low confidence, 1 Class II study 26 ).
People with tics receiving risperidone are possibly more likely to require antiparkinsonian medication than people receiving placebo (low confidence, 1 Class II study 26 ).
Blood pressure
People with tics and a comorbid diagnosis of ADHD receiving desipramine are possibly more likely to have an increase in diastolic blood pressure than people receiving placebo (low confidence, 1 Class II study 36 ) (children only).
Heart rate
People with tics and a comorbid diagnosis of ADHD receiving atomoxetine are possibly more likely to have an increase in heart rate than people receiving placebo (low confidence, 1 Class II study 49 ) (children only).
People with tics and a comorbid diagnosis of ADHD receiving desipramine are possibly more likely to have an increased heart rate than people receiving placebo (low confidence, 1 Class II study 36 ) (children only).
ECG changes
People with tics receiving pimozide are possibly more likely to have a prolonged QT interval than people receiving placebo and haloperidol (low confidence, 1 Class II study 25 ).
Discussion
This systematic review summarizes the evidence for efficacy and harms of interventions for the treatment of tics in individuals with TS and chronic tic disorders. While there is evidence to support the efficacy of several treatments, knowledge gaps remain. Many of the interventions have only been studied in one randomized controlled trial of short duration, with modest sample sizes. The inherent features of tic disorders, with waxing and waning of symptoms over time, placebo effects, as well as suppression of tics during clinical encounters, may confound symptom assessment in clinical trials. There remains a great need for randomized controlled trials of interventions for tics to further evaluate both longterm efficacy and safety. The accompanying practice guideline makes recommendations based on the findings of this systematic review, acknowledging the limitations of the currently available evidence and strongly encouraging psychoeducation and shared decision-making regarding treatment needs and priorities.
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Disclaimer
Practice guidelines, practice advisories, comprehensive systematic reviews, focused systematic reviews, and other guidance published by the AAN and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information: (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. AAN provides this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.
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